COLO 668Homo sapiens (Human)Cancer cell line
Also known as: Colorado 668, Colo668, COLO668, COLO-668, Colo 668
Quick Overview
COLO 668 is a human cell line derived from a small cell lung carcinoma, known for BRAF V599E mutation and used in cancer research.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1128 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Brain[UBERON:UBERON_0000955] |
Donor Information
| Age | 47 |
|---|---|
| Age Category | Adult |
| Sex | Female |
Disease Information
| Disease | Small cell lung cancer |
|---|---|
| Lineage | Lung |
| Subtype | Small Cell Lung Cancer |
| OncoTree Code | SCLC |
DepMap Information
| Source Type | ECACC |
|---|---|
| Source ID | ACH-000803_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Gly245Cys (c.733G>T) | Heterozygous | Somatic mutation acquired during proliferation | PubMed=18487078, PubMed=16020667, PubMed=15287027, PubMed=12884349, PubMed=1394225 |
| MutationSimple | RB1 | p.Gln436Ter (c.1306C>T) | Heterozygous | - | Unknown, Unknown |
| MutationSimple | RB1 | p.Leu337Trpfs*12 (c.1010delG) | Heterozygous | - | Unknown, Unknown |
| MutationSimple | KRAS | p.Gly12Val (c.35G>T) | Heterozygous | Acquired | Unknown, Unknown |
| MutationSimple | BRAF | p.Val600Glu (c.1799T>A) | Unspecified | - | PubMed=26214590 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
Mutational analysis of the BRAF gene in human tumor cells.";
Noda S.
Hum. Cell 21:13-17(2008).
Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles.
Nakagawa K., Nomura H., Ishikawa Y.
Lancet 363:775-781(2004).